BioVaxys Technology Corp. Closes First Tranche of Private Placement
// THIS PRESS RELEASE IS NOT INTENDED FOR RELEASE OR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, May 3, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the “Company“) is pleased to announce that it has closed the first tranche (the “First Tranche“) of its previously announced non-brokered private placement (the “Private Placement“) with the issuance of 5,126,574 units (the “Units“) of the Company at a price of $0.065 per Unit for aggregate gross proceeds of $333,227.31.
Related news for (BVAXF)
- BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
- BioVaxys Technology Corp. Granted Management Cease Trade Order
- Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
- Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
- BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT